Metabolic cofactor and antioxidant · Fact sheet

Alpha-lipoic acid

Also known as ALA · Thioctic acid

Alpha-lipoic acid has human research on diabetic nerve symptoms. Short-term symptom improvement does not establish nerve regeneration, and a large long-term trial missed its primary endpoint.

Not FDA approvedModerate human evidence

What is Alpha-lipoic acid?

Alpha-lipoic acid participates in cellular energy metabolism. It is different from alpha-linolenic acid, a fatty acid also abbreviated ALA.

Benefits & claims

Nerve pain, glucose control, antioxidant effects, and healthy aging are common interests. Diabetic neuropathy findings cannot be generalized to every cause of nerve symptoms.

What the evidence supports

  • Short-term randomized evidence supports improvement in some diabetic neuropathy symptoms.
  • Long-term findings do not establish that ALA reverses nerve damage or prevents disability.
Research areas
  • Diabetic polyneuropathy
  • Neuropathic symptoms
  • Metabolic biomarkers

Dosage & frequency

Human study context

An oral diabetic-neuropathy trial provides a concrete study dose; it does not establish a general wellness or longevity prescription.

SYDNEY 2 randomized trial

181 patients with diabetic distal symmetric polyneuropathy

Amount
600, 1,200 or 1,800 mg in separate study groups
Frequency
Once daily for five weeks
Route studied or labeled
Oral

Trial-specific neuropathy outcomes; not a general wellness regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Oral alpha-lipoic acid and intravenous preparations have different evidence.
  • A study of ALA does not establish equivalence for every R-ALA or racemic supplement.

Interactions & precautions

  • The neuropathy trial does not provide a comprehensive interaction assessment for every diabetes medicine or ALA supplement formulation.

What is still unresolved

  • Long-term benefits outside the studied neuropathy population remain uncertain.

Side effects & risks

  • Nausea, vomiting, and vertigo increased with exposure in the short-term trial.
  • NATHAN 1 reported more serious adverse events in the ALA group; the imbalance does not establish that every event was caused by ALA.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

The five-week SYDNEY 2 study enrolled 181 adults with diabetic polyneuropathy. The four-year NATHAN 1 study enrolled 460 and did not significantly improve its primary combined endpoint, despite some favorable secondary findings.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Pain: reported experiences

Positive account · personal report

Less foot discomfort over several months

A person with foot neuropathy described gradual symptom improvement after adding ALA, with pain returning during a break. They had previously used gabapentin.

Reported use in this account

Product
Product described as ALA; formulation not stated
Amount
Not specified clearly
Frequency
Daily
Route
Not specified clearly
Duration
A few months

Other exposures described: Gabapentin earlier in the course; subsequently stopped, according to the author

The earlier gabapentin exposure and natural symptom changes cannot be separated from the reported improvement. The author's amount reply omits a unit, so no amount can be resolved; product contents were not verified.

Read the foot-symptom account
No noticeable effect · personal report

No symptom change over several months

Another person with self-described idiopathic peripheral neuropathy reported no difference during several months of ALA use or afterward.

Reported use in this account

Product
Product described as ALA; formulation not stated
Amount
1,800 mg
Frequency
Daily
Route
Not specified clearly
Duration
Many months

Neuropathy type and clinical outcomes were not confirmed. This does not predict another person's response.

Read the no-improvement account

Approval status

Alpha-lipoic acid has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.

Supplement research is not FDA drug approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term effects on disability or nerve regeneration
  • Applicability to non-diabetic neuropathy
  • Safety and interactions across preparations

Summary

Long-term findings do not establish that ALA reverses nerve damage or prevents disability.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedSYDNEY 2: alpha-lipoic acid and diabetic neuropathy symptoms

    181-person, five-week randomized trial with gastrointestinal and dizziness effects.

  2. pubmedNATHAN 1: four-year alpha-lipoic acid trial

    460 participants; primary endpoint not significant and secondary findings require context.

  3. fdaFDA: what approval means for supplements

    Dietary supplements are not approved by FDA for safety and effectiveness before marketing.

How we assess sources · Suggest a correction